Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 84.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 240,817 shares of the company's stock after buying an additional 110,020 shares during the period. Victory Capital Management Inc. owned approximately 0.40% of Protagonist Therapeutics worth $9,296,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. FNY Investment Advisers LLC acquired a new stake in Protagonist Therapeutics in the fourth quarter valued at approximately $38,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Protagonist Therapeutics during the 3rd quarter valued at $69,000. KBC Group NV boosted its position in shares of Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock worth $121,000 after purchasing an additional 295 shares in the last quarter. Finally, Caprock Group LLC purchased a new position in Protagonist Therapeutics during the 4th quarter worth $224,000. Hedge funds and other institutional investors own 98.63% of the company's stock.

Insider Transactions at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the transaction, the chief executive officer now directly owns 540,260 shares in the company, valued at approximately $20,627,126.80. This represents a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Arturo Md Molina sold 30,514 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total value of $1,700,850.36. Following the sale, the insider now directly owns 83,892 shares of the company's stock, valued at approximately $4,676,140.08. This trade represents a 26.67 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,776 shares of company stock valued at $3,368,010. Corporate insiders own 5.40% of the company's stock.

Remove Ads

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock traded down $1.77 during trading on Monday, hitting $53.01. 1,284,601 shares of the company's stock were exchanged, compared to its average volume of 739,534. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of 19.93 and a beta of 2.34. The business has a 50-day simple moving average of $39.63 and a 200-day simple moving average of $42.23.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. On average, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PTGX shares. StockNews.com cut Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. JPMorgan Chase & Co. increased their price objective on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a research report on Tuesday, March 4th. BMO Capital Markets boosted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Wedbush restated an "outperform" rating on shares of Protagonist Therapeutics in a research note on Tuesday, March 11th. Finally, The Goldman Sachs Group dropped their price objective on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, February 24th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.22.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.